These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 21692765

  • 1. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR, Pedersen M, Jørgensen B, Søndergaard K, Jensen JD, Ramsing M, Olesen AB.
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [Abstract] [Full Text] [Related]

  • 2. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S, Walter S, Witzke O, Kreuter A, Kribben A, Mitchell A.
    Nephron Clin Pract; 2012 Oct; 121(1-2):c91-4. PubMed ID: 23182840
    [Abstract] [Full Text] [Related]

  • 3. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [Abstract] [Full Text] [Related]

  • 4. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS.
    J Comput Assist Tomogr; 2009 Apr; 33(6):819-23. PubMed ID: 19940643
    [Abstract] [Full Text] [Related]

  • 5. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG, Reilly RF.
    Semin Dial; 2011 Apr; 24(5):480-6. PubMed ID: 21913988
    [Abstract] [Full Text] [Related]

  • 6. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
    Amet S, Launay-Vacher V, Clément O, Frances C, Tricotel A, Stengel B, Gauvrit JY, Grenier N, Reinhardt G, Janus N, Choukroun G, Laville M, Deray G.
    Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
    [Abstract] [Full Text] [Related]

  • 7. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN.
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [Abstract] [Full Text] [Related]

  • 8. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
    Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR.
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
    [Abstract] [Full Text] [Related]

  • 9. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A.
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [Abstract] [Full Text] [Related]

  • 10. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH.
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [Abstract] [Full Text] [Related]

  • 11. Incidence of nephrogenic systemic fibrosis at two large medical centers.
    Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM.
    Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
    [Abstract] [Full Text] [Related]

  • 12. The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis.
    Hashemi P, Sina B, Rietkerk W, Safai B.
    J Nephrol; 2013 Sep; 26(1):48-54. PubMed ID: 22573525
    [Abstract] [Full Text] [Related]

  • 13. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H.
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [Abstract] [Full Text] [Related]

  • 14. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS.
    JAMA Intern Med; 2020 Feb 01; 180(2):223-230. PubMed ID: 31816007
    [Abstract] [Full Text] [Related]

  • 15. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER, Semelka RC.
    Radiology; 2009 Dec 01; 253(3):689-96. PubMed ID: 19789233
    [Abstract] [Full Text] [Related]

  • 16. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
    Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA.
    Radiology; 2009 Feb 01; 250(2):371-7. PubMed ID: 19188312
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G, Neruda A, Watschinger B, Vychytil A, Geusau A, Haumer M, Weber M.
    Eur J Radiol; 2010 Oct 01; 76(1):129-34. PubMed ID: 19619969
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis: center case review.
    Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-Parker S, Martin DR.
    J Magn Reson Imaging; 2007 Nov 01; 26(5):1198-203. PubMed ID: 17969162
    [Abstract] [Full Text] [Related]

  • 19. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC, Abu-Alfa AK.
    J Magn Reson Imaging; 2009 Dec 01; 30(6):1236-9. PubMed ID: 19938035
    [Abstract] [Full Text] [Related]

  • 20. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
    Alfano G, Fontana F, Ferrari A, Solazzo A, Perrone R, Giaroni F, Torricelli P, Cappelli G.
    Magn Reson Imaging; 2020 Jul 01; 70():1-4. PubMed ID: 32112811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.